Allergan AGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 2-Actavis expects Allergan business to drive 2015 growth


      Mon, 11 May 2015

      * Expects 2015 rev of $20.5-$21 bln; adj rev of $22-$22.5 bln

    2. Actavis revenue jumps 60 pct


      Mon, 11 May 2015

      May 11 (Reuters) - Drugmaker Actavis Plc's quarterly revenue jumped almost 60 percent, helped by higher sales of its branded drugs in North America, but charges related to its acquisition of Botox maker Allergan Inc pushed the company into a net loss.

    3. Actavis Reports Strong 1Q Results as Integration of Allergan Begins


      Mon, 11 May 2015

      for the company, the integration of Allergan (following the deal close March 17 ..... contribution from the acquisition of Allergan . Actavis' brand segment reported 5% growth excluding Allergan 's sales, with most reported drug segments

    4. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019


      Tue, 21 Apr 2015

      International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon Laboratories Inc. - Alimera Sciences Inc. - Allergan Inc . - Ampio Pharmaceuticals Inc. - Antisense Therapeutics Ltd. - Bausch & Lomb Inc. - BCN Peptides SA - Boehringer

    5. Mylan Makes Offer for Perrigo in Attempt to Diversify Generic Operations


      Wed, 8 Apr 2015

      Procter & Gamble combined with Actavis’ and Valeant’s high financial leverage after their recent deals for Salix and Allergan , respectively, could hinder additional bids. We’re raising our stand-alone fair value estimate for Perrigo to $150

    6. Health Care: 3 Picks in a More Expensive Sector


      Wed, 1 Apr 2015

      through creating scale, cutting costs, and focusing on key strategic areas. We see this trend with the pending acquisition of Allergan by Actavis. This trend is also evident with Valeant 's VRX bid for Salix (which may subsequently get outbid by Endo ENDP

    7. Actavis' Wide-Moat Transformation Offers Shareholder Rewards


      Mon, 23 Mar 2015

      wide-moat operations following the Allergan acquisition. From Weak Generic to Major ..... Irish domicile. With the close of the Allergan acquisition, Actavis will have pro forma ..... flow in excess of $8 billion. Legacy Allergan , Forest, and Warner sales will represent

    8. A Wide-Moat Opportunity in Health Care

      Video Reports

      Wed, 11 Mar 2015

      with pro forma sales after the Allergan ( AGN ) deal on par with big players ..... a lot of that is inherited from Allergan , but we think there is a lot of ..... cost synergies from the recent Allergan deal. We currently have a $330

      Allergan AGN found at 0:18

      to a very large branded-pharmaceutical firm with pro forma sales after the Allergan ( AGN ) deal on par with big players like Eli Lilly (LLY) and GlaxoSmithKline (GSK). We like the business and we give it a
    9. Complexities of Eye Care Drive Strong Moats


      Fri, 6 Mar 2015

      ophthalmology drugmakers, especially Allergan AGN and Novartis, have enjoyed success ..... rolling out new dosage strengths ( Allergan 's Lumigan 0.03% to 0.01 ..... preservative-free products ( Allergan 's Alphagan to Alphagan P

    10. Ultimate Stock-Pickers' Top 10 Buys and Sells


      Tue, 3 Mar 2015

      WellsFargo WFC 3 Medium Narrow 54.79 1.05 282,581 5 Allergan AGN 3 Medium Wide 232.74 1.03 70,358 3 Occidental ..... acquisitions announced during the period (with wide-moat Allergan AGN fitting the bill this time around). With regards to

    « Prev12345Next »
    Content Partners